Emerald Mutual Fund Advisers Trust’s Akero Therapeutics AKRO Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-110,747	Closed	-$5.26M	–	191
2025 Q3	$5.26M	Sell	110,747 -25,550	-19%	-$1.24M	0.27%	103
2025 Q2	$7.27M	Sell	136,297 -70,738	-34%	-$3.21M	0.44%	84
2025 Q1	$8.38M	Sell	207,035 -145,145	-41%	-$6.15M	0.59%	68
2024 Q4	$9.8M	Sell	352,180 -63,021	-15%	-$1.91M	0.6%	64
2024 Q3	$11.9M	Sell	415,201 -9,700	-2%	-$253K	0.62%	66
2024 Q2	$9.97M	Hold	424,901	–	–	0.52%	68
2024 Q1	$10.7M	Buy	424,901 +308,820	+266%	+$7.42M	0.56%	77
2023 Q4	$2.71M	Buy	+116,081	New	+$2.29M	0.14%	121

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's AKRO Position: Q4 2025 in Review

Emerald Mutual Fund Advisers Trust sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 110,747 shares — an estimated $5.26M sold.

Emerald Mutual Fund Advisers Trust first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $11.9M in Q3 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Emerald Mutual Fund Advisers Trust reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 110,747 Akero Therapeutics shares in Q4 2025, an estimated $5.26M.
Emerald Mutual Fund Advisers Trust first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
Emerald Mutual Fund Advisers Trust's Akero Therapeutics position peaked at $11.9M in Q3 2024.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2025, filed 9 Feb 2026.